Effect of pioglitazone treatment on behavioral symptoms in autistic children

  • Marvin Boris1Email author,

    Affiliated with

    • Claudia C Kaiser2,

      Affiliated with

      • Allan Goldblatt1,

        Affiliated with

        • Michael W Elice1,

          Affiliated with

          • Stephen M Edelson3,

            Affiliated with

            • James B Adams4 and

              Affiliated with

              • Douglas L Feinstein2

                Affiliated with

                Journal of Neuroinflammation20074:3

                DOI: 10.1186/1742-2094-4-3

                Received: 13 November 2006

                Accepted: 05 January 2007

                Published: 05 January 2007



                Autism is complex neuro-developmental disorder which has a symptomatic diagnosis in patients characterized by disorders in language/communication, behavior, and social interactions. The exact causes for autism are largely unknown, but is has been speculated that immune and inflammatory responses, particularly those of Th2 type, may be involved. Thiazolidinediones (TZDs) are agonists of the peroxisome proliferator activated receptor gamma (PPARγ), a nuclear hormone receptor which modulates insulin sensitivity, and have been shown to induce apoptosis in activated T-lymphocytes and exert anti-inflammatory effects in glial cells. The TZD pioglitazone (Actos) is an FDA-approved PPARγ agonist used to treat type 2 diabetes, with a good safety profile, currently being tested in clinical trials of other neurological diseases including AD and MS. We therefore tested the safety and therapeutic potential of oral pioglitazone in a small cohort of children with diagnosed autism.

                Case description

                The rationale and risks of taking pioglitazone were explained to the parents, consent was obtained, and treatment was initiated at either 30 or 60 mg per day p.o. A total of 25 children (average age 7.9 ± 0.7 year old) were enrolled. Safety was assessed by measurements of metabolic profiles and blood pressure; effects on behavioral symptoms were assessed by the Aberrant Behavior Checklist (ABC), which measures hyperactivity, inappropriate speech, irritability, lethargy, and stereotypy, done at baseline and after 3–4 months of treatment.

                Discussion and evaluation

                In a small cohort of autistic children, daily treatment with 30 or 60 mg p.o. pioglitazone for 3–4 months induced apparent clinical improvement without adverse events. There were no adverse effects noted and behavioral measurements revealed a significant decrease in 4 out of 5 subcategories (irritability, lethargy, stereotypy, and hyperactivity). Improved behaviors were inversely correlated with patient age, indicating stronger effects on the younger patients.


                Pioglitazone should be considered for further testing of therapeutic potential in autistic patients.


                Autism, the most common of the group of disorders collectively referred to as Autism Spectrum Disorders (ASD), is a complex neurological disease of unknown etiology. The incidence of autism is estimated to be 1 per 166 [1] with a male to female ratio of 4:1. Autism has been found throughout the world in families of all racial, ethnic and social backgrounds. Although accumulating evidence suggests that genetic, environmental, inflammatory, immunological, and metabolic factors play a prominent role in this disease [27], the precise causes remain to be determined.

                Altered immune responses in children with ASD are well documented. Autoimmune disorders of thyroiditis, colitis, myelin basic protein autoantibodies, and diabetes are prevalent in children with ASD. Stubbs (1976) published that 5 of 13 autistic children had no detectable rubella antibodies despite prior immunization [7]. An additional study showed peripheral mononuclear cells had a decreased proliferative response to mitogenic stimulation compared to normal children [8]. These findings of abnormal T-lymphocyte function have been replicated by other investigators [9, 10]. Inflammatory responses in ASD have also been reported to occur in brain, for example neuroinflammatory processes involving both microglia and astroglia were found on post mortem examination in autistic children with elevated cytokine levels in the cerebral spinal fluid [11, 12]. Children with ASD have increased cytokines of Th2 and Th1 arms of the immune response with Th2 predominant without an increase in IL10 [13].

                Peroxisome proliferator-activated receptor gamma (PPARγ) is a nuclear hormone receptor originally characterized by its ability to regulate adipocyte differentiation and gene transcription [14]. PPARγ agonists include fatty acids, non-steroidal anti-inflammatory drugs (NSAIDs), the natural compound 15-deoxy12,14-prostaglandin-J2 (PGJ2), and members of the class of synthetic drugs termed thiazolidinediones (TZDs) which include pioglitazone (Actos) and rosiglitazone (Avandia). TZDs were originally designed as anti-diabetic drugs due to their insulin sensitizing effects, and several are now in clinical use. In addition to insulin sensitizing effects, TZDs also exert anti-inflammatory effects on a variety of cell types, and for this reason some are being considered for treatment of inflammatory diseases including artherosclerosis [15], psoriasis [16, 17], and inflammatory bowel disease [1821]. TZDs also reduce inflammatory activation of brain glial cells, and increase metabolic activities in glial cells which can lead to increased glucose uptake, lactate production, and mitochondrial function [22, 23]. Furthermore, pioglitazone can cross the BBB, [24] suggesting possible direct effects on brain physiology, which could positively influence possible abnormalities in regional brain glucose utilization [25] or dysregulation of functional activity [26] as reported to occur ASD.

                The safety and efficacy of pioglitazone has been established by clinical studies worldwide [27, 28] and since FDA approval, pioglitazone has been prescribed to several million patients. The adverse events associated with TZDs including pioglitazone are generally mild and transient, and those effects returned to baseline upon withdrawal from, or completion of the studies. Two recent studies for the treatment of diabetes in adolescents point to a good safety profile for Actos in younger populations [29, 30]. Studies with PPARγ drugs in animal models of neurological conditions have led to clinical testing of these drugs in Alzheimer's disease (AD) and multiple sclerosis (MS) [31, 32]. These properties of PPARγ agonists make them promising candidates for a therapeutic approach to influence the clinical course of ASD. In this report we discuss initial findings using pioglitazone to treat children with autism, which provides the rationale for design of larger clinical trials.

                Case description


                The autistic children all were patients of Marvin Boris, MD, Allan Goldblatt, PA, and Michael Elice, MD. Twenty-five children and adolescents participated in this study. The mean age was 7.9 ± 3.5 years, with a range from 3 to 17 years. There were 22 males and 3 females. All of the participants received an independent diagnosis of Autism Spectrums Disorder (ASD) from an independent clinician and/or agency. None of the children had diagnosed Asperger's Disorder (a mild variant of ASD with higher social functioning) or PDDNOS (Pervasive Developmental Disorder – Not Otherwise Specified, a condition with social or behavioral impairments but which do not meet the DSM-IV criteria for ASD). The diagnosis of autism was initially established by a board certified pediatric neurologist, developmental pediatrician, or psychiatrist with experience in ASD. In addition, at the first visit to the offices of the treating physician, the child had to meet the DSM-IV checklist criteria for ASD. All the children had been receiving behavioral and educational therapies. These included speech, occupational, and physical therapy, applied behavioral analysis, and auditory integration therapy. The children had also received various biomedical interventions for at least one year. These included dairy and gluten free diet, metabolic treatment with supplements to known deficiencies such as MTHFR (methylenetetrahydrofolate reductase), treatment with intravenous gamma globulin or secretin, vitamin supplementation, and heavy metal chelation. The children who responded poorly (no noticeable improvements in cognitive, social, behavior, or language skills) for at least one year to biomedical, behavioral, or educational therapies were selected to be treated with pioglitazone as part of the routine health care treatment, based on papers suggesting that ASD includes an auto-immune or inflammatory component [33, 34], and that pioglitazone can reduce T-cell activation and Th2-type cytokine production, both implicated in ASD [3538]. The rationale and risks of taking pioglitazone were explained to the parents, and parental written consents were obtained for all participants. A retrospective review of their personal medical records was approved by the Internal Review Board of Arizona State University.


                The autistic population has well-known auto-immunne comorbidities. In this group of autistic children, 7/25 (28%) had thyroiditis, 8/25 (32%) had colitis, 8/25 (32%) had PANDAS (Pediatric acquired neurological disorder associated with streptococcus), 20/25 (80%) had allergic diseases, and 7/25 (28%) were positive for serum antibodies to myelin basic protein. In addition 2/25 had seizures prior to being treated with pioglitazone.


                Children were prescribed pioglitazone either 30 mg per day, p.o. for ages 3–5 years old; or 60 mg per day for ages 6–17 years old. These children were followed with monthly complete blood counts, glucose and insulin levels, and serum metabolic assays.


                The participants' parents completed the Aberrant Behavior Checklist (ABC) prior to the administration of pioglitazone and then at a follow-up assessment, 12 or 16 weeks later. There are five subscales on the ABC, consisting of 58 questions. The subscales are: hyperactivity, inappropriate speech, irritability, lethargy, and stereotypy. Each question was rated on a 4-point scale: 0 = 'not a problem,' 1 = 'the behavior is a problem but slight in degree,' 2 = 'the problem is moderately serious,' and 3 = 'the problem is severe in degree.' 'The ABC has been shown to be a valid and reliable procedure to evaluate treatment efficacy [3941]. Each of the five subscales was analyzed using paired t-tests. The relationship between age and amount of behavior change was examined using Pearson product correlations


                There were no significant abnormalities observed in standard blood analyses in the group of 25 autistic children treated with pioglitazone for up to 4 months (Table 1). Over the course of treatment, there were no elevations in hemoglobin, creatine, BUN (blood urea nitrogen) or insulin levels. There were 2 incidents of slightly and transiently elevated white blood counts and glucose levels, and 3 incidents of slightly and transiently elevated liver enzyme (ALT and AST) levels. All elevations resolved without interventions.
                Table 1

                Incidents of elevated blood values






                WBC 1





                Glucose 2





                AST 3





                ALT 4,5





                1White blood cell counts, normal range 3.8 to 10.5 × 1000 cells per mcl. Values of 11.0 and 12.0 recorded. 2Glucose, normal range 70–99 mg/dl. Values of 102 and 106 recorded. 3Aspartate aminotransferase, normal range 10–40 IU/L. Values of 42, 48, and 45 recorded. 4Alanine aminotransferase, normal range 10–45 IU/L. Values of 56, 60, and 48 recorded. 5ALT and AST elevations occurred in the same three patients. 6Pre, pre-trial; Mid, mid-trial; Post, post-trial.

                A comparison of the mean scores for ABC subscales between baseline and end of treatment for each of the patients revealed that four of the five ABC subscales decreased significantly following the administration of pioglitazone (Figure 1). These subscales were hyperactivity, irritability, lethargy, and stereotypy. There was no change in inappropriate speech; however, it should be noted that the speech subscale is of limited value in children with autism who lack or have very limited speech.
                Figure 1

                Effect of Pioglitazone on behavior improvement. The average (mean ± s.d.) of the total scores for the 5 subscales of the ABC was calculated for 25 patients before treatment (baseline) and after 3–4 months of treatment with Pioglitazone. *, P < .05 unpaired T-test.

                Of the 25 patients, 76% showed an improvement (defined as >50% decrease in score) in at least one subgroup; while 56% showed an improvement in two or more subgroups, and 40% showed improvements in 3 or more subcategories. If response rate is estimated as those who showed >25% decrease in at least 2 of the 5 subscales, then the percentage is much higher 71%. The majority of patients (52%) showed an improvement (>50%) in the hyperactivity subscale.

                Significant inverse correlations (Figure 2) were detected between age and the improvements calculated for irritability (P = 0.03), lethargy (P = 0.02) and hyperactivity (P = 0.007). This indicates a tendency for younger participants to benefit more from pioglitazone than the older participants.
                Figure 2

                Relationship of behavioral improvements to age. Differences in scores for the 5 subscales of the ABC were calculated and plotted versus patient age, and analyzed using Graphpad Prism V4 assuming Gaussian distributions.

                Discussion and evaluation

                The current study provides evidence that treatment with the PPARγ agonist pioglitazone (Actos) does not induce any significant adverse effects, and may have a beneficial effect on patterns of aberrant social behavior in children with diagnosed autism. Despite the small sample size (n = 25 total), we observed statistically significant decreases in 4 of the 5 subscales of the ABC after a relatively short (4 months) treatment with pioglitazone. It is yet not known if these improvements are long lasting, or if they will continue after treatment is withdrawn. Although originally approved for treatment of Type 2 diabetes in adults, recent clinical trials of pioglitazone for treatment of diabetes in adolescents suggest this drug will be well tolerated in younger populations [29, 30].

                There is increasing evidence for an association of ASD with various immune syndromes. It was reported that 66% of children with autism have a relative with an autoimmune disease [42], and families of children with PDD (Pervasive Development Disorder) have a higher average number of autoimmune diseases than families of healthy children [43]. Recently the occurrence of AITD (Autoimmune Thyroid Disease) in first or second order relatives was concluded to be a risk factor for those ASD children who show regression (the early loss of already established skills of communication or of social interactions) [44]. The possibility therefore exists that pioglitazone influences some aspect of auto-immune nature in ASD children.

                It has been suggested that a Th2-like dysfunction may contribute to the causes of ASD. In children with ASD, a preponderance of Th2-like (IL4, IL6, IL10) over Th1-like (IL2, IFNg, IL1β) cytokines has been reported [4548]. These studies support the idea that a predominance of Th2 cytokines may be a factor in ASD. PPARγ agonists are known to influence T-cell physiology, and although most often they have been shown to reduce Th1-like cytokine (IL1β, TNFa, IL12) production, in several studies they also reduced Th2 responses. In CD4 cells, PGJ2 and the TZD ciglitazone reduced IL4 production [35] and in EAE, the animal model of Multiple Sclerosis, PGJ2 blocked splenic T cell production of IL10 and IL4 [36]. PPARγ agonists also reduce the clinical symptoms in animal models of asthma, a disease which is also thought to be predominantly Th2 type involving IL4, IL5, and IL13 [37]. PPARγ agonists have been shown to reduce IL4, IL5, and IL13 production from Tcells of mice with induced lung inflammation [38, 49]. However, in one study the TZDs increased IL4 and IL10, and stimulated GATA3 expression (a transcription factor which shifts cells towards Th2 phenotype) [50]; although in other studies PPARγ drugs were shown to inhibit GATA3 activity [51, 52]. Nevertheless, taken together these studies demonstrate that PPARγ agonists have the potential to shift the T-cell response from Th2 to Th1, or to reduce Th2 cytokine expression, which may be of therapeutic benefit in ASD.

                Despite observing significant improvements in 4 of 5 subscales of the ABC, the open-label nature of this study limits the ability to draw strong conclusions regarding treatment-dependent benefits. In addition, well-known expectancy effects in the parent population make interpretation of the ABC subject to potential bias [53, 54]. The placebo effect in ASD has been reported to be high in some studies where improvement was assessed using the ABC. Improvements occurred in 25% of patients following atomoxetine treatment for 6 weeks, [55]; 34% after 8 week treatment with risperidone [56]; and 37% after 3 weeks treatment with amantadine [54]. In the current study, the number of responders (those showing >50% improvement in at least one subscale) was 76%, considerably higher than the values reported in the above studies.

                An additional confound of the current study is the diversity of auto-immune comorbidities that are common in the autistic population. It is possible that pioglitazone effects are, in part or in full, an indirect consequence of reducing symptoms of the autoimmune diseases present in the study population (thyroiditis, colitis, and PANDAS). For example, in autoimmune thyroiditis (AITD), pioglitazone could increase levels of suppressor T-cells that are deficient [57] and as a result reduce circulating levels of Th1 or Th2 cytokines. Similarly, activation of PPARγ can suppress experimentally induced colitis [58] which could also reduce plasma cytokine levels, and in fact several clinical trials of PPARγ agonists for treating colitis are in progress [19, 59]. PANDAS, a pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections is defined by obsessive-compulsive (OCD) and or tic disorders, is thought to be due to the actions of auto-immune antibodies on basal ganglia neurons [60], and is improved by immunomodulatory therapies [61]; anti-inflammatory effects of PPARγ agonists could therefore influence the course of this disease. However, since the precise relationships between autoimmune diseases and the penetrance of autistic symptoms remains to be established, deciphering the relative importance of indirect effect of pioglitazone on behavior will be a formidable task.

                The recent increase in type 2 diabetes in children has resulted in an increased interest of researchers to explore the use of anti-diabetic drugs including TZDs in children, therefore providing additional information regarding the safety of TZDs in this population. A recent clinical trial tested the effects of rosiglitazone (2 mg bid increased to 4 mg bid after 8 weeks), a related TZD, in 195 obese type 2 diabetic children (age range 8–17 years), in a 24-week double-blind, randomized, metformin-controlled, parallel group design. The rosiglitazone group gained ~3 kg after 24 weeks with the occurrence of peripheral edema in 1 child [29]. However, no other adverse effects were reported, suggesting that TZDs are well tolerated in children as in adults. More recently [30] pioglitazone (15 mg po escalated to 30 mg po after 4 weeks) was tested as an adjunct therapy for the treatment of type 1 diabetes in a small group of young adolescents (age range 10–17.9 years). After 6 months treatment the pioglitazone subjects showed a small but significant increase in BMI z-score (body mass index standard deviation for age) suggesting treatment-related weight gain. In the 35 subjects who completed the study, there was no evidence of edema, anemia, or of any significant increase in the frequency of hypoglycemia in the treatment group versus the placebo group. However, it is clear that the safety of pioglitazone, and of other TZDs, in the pediatric population requires additional testing.


                In view of its established safety profile, the current results provide the rationale for further testing of pioglitazone in autism and other forms of ASD.



                Aberrant Behavior Checklist


                Alzheimer's disease


                Autism Spectrum Disorder


                Blood brain barrier


                Complete blood count


                Cluster of differentiation




                Multiple Sclerosis


                Non steroidal anti-inflammatory drug


                Pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections


                15-deoxy-delta12,14-prostaglandin J2


                pervasive developmental disorder


                Peroxisome proliferator activated receptor


                Tumor necrosis factor





                The authors wish to acknowledge the financial assistance of the Autism Research Institute (San Diego, CA) and dedicate this study to the memory of its founder Dr Bernard Rimland,

                Authors’ Affiliations

                77 Froehlich Farm Blvd Woodbury
                Department of Anesthesiology, University of Illinois
                Autism Research Institute
                Arizona State University


                1. Polak PE, Kalinin S, Dello RC, Gavrilyuk V, Sharp A, Peters JM, Richardson J, Willson TM, Weinberg G, Feinstein DL: Protective effects of a peroxisome proliferator-activated receptor-beta/delta agonist in experimental autoimmune encephalomyelitis. J Neuroimmunol 2005, 168:65–75.View ArticlePubMed
                2. Rapin I, Katzman R: Neurobiology of autism. Ann Neurol 1998, 43:7–14.View ArticlePubMed
                3. Newschaffer CJ, Fallin D, Lee NL: Heritable and nonheritable risk factors for autism spectrum disorders. Epidemiol Rev 2002, 24:137–153.View ArticlePubMed
                4. Folstein SE, Rosen-Sheidley B: Genetics of autism: complex aetiology for a heterogeneous disorder. Nat Rev Genet 2001, 2:943–955.View ArticlePubMed
                5. Korvatska E, Van de WJ, Anders TF, Gershwin ME: Genetic and immunologic considerations in autism. Neurobiol Dis 2002, 9:107–125.View ArticlePubMed
                6. Lipkin WI, Hornig M: Microbiology and immunology of autism spectrum disorders. Novartis Found Symp 2003, 251:129–143.View ArticlePubMed
                7. Stubbs EG: Autistic children exhibit undetectable hemagglutination-inhibition antibody titers despite previous rubella vaccination. J Autism Child Schizophr 1976, 6:269–274.View ArticlePubMed
                8. Stubbs EG, Crawford ML: Depressed lymphocyte responsiveness in autistic children. J Autism Child Schizophr 1977, 7:49–55.View ArticlePubMed
                9. Warren RP, Margaretten NC, Pace NC, Foster A: Immune abnormalities in patients with autism. J Autism Dev Disord 1986, 16:189–197.View ArticlePubMed
                10. Denney DR, Frei BW, Gaffney GR: Lymphocyte subsets and interleukin-2 receptors in autistic children. J Autism Dev Disord 1996, 26:87–97.View ArticlePubMed
                11. Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA: Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol 2005, 57:67–81.View ArticlePubMed
                12. Pardo CA, Vargas DL, Zimmerman AW: Immunity, neuroglia and neuroinflammation in autism. Int Rev Psychiatry 2005, 17:485–495.View ArticlePubMed
                13. Molloy CA, Morrow AL, Meinzen-Derr J, Schleifer K, Dienger K, Manning-Court, Altaye M, Wills-Karp M: Elevated cytokine levels in children with autism spectrum disorder. J Neuroimmunol 2006, 172:198–205.View ArticlePubMed
                14. Berger J, Wagner JA: Physiological and therapeutic roles of peroxisome proliferator-activated receptors. Diabetes Technol Ther 2002, 4:163–174.View ArticlePubMed
                15. Duval C, Chinetti G, Trottein F, Fruchart JC, Staels B: The role of PPARs in atherosclerosis. Trends Mol Med 2002, 8:422–430.View ArticlePubMed
                16. Bongartz T, Coras B, Vogt T, Scholmerich J, Muller-Ladner U: Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: an open-label pilot study. Rheumatology (Oxford) 2005, 44:126–129.View Article
                17. Gniadecki R, Calverley MJ: Emerging drugs in psoriasis. Expert Opin Emerg Drugs 2002, 7:69–90.View ArticlePubMed
                18. Katayama K, Wada K, Nakajima A, Mizuguchi H, Hayakawa T, Nakagawa S, Kadowaki T, Nagai R, Kamisaki Y, Blumberg RS, Mayumi T: A novel PPAR gamma gene therapy to control inflammation associated with inflammatory bowel disease in a murine model. Gastroenterology 2003, 124:1315–1324.View ArticlePubMed
                19. Liang HL, Ouyang Q: [A clinical trial of rosiglitazone and 5-aminosalicylate combination for ulcerative colitis]. Zhonghua Nei Ke Za Zhi 2006, 45:548–551.PubMed
                20. Lewis JD, Lichtenstein GR, Stein RB, Deren JJ, Judge TA, Fogt F, Furth EE, Demissie EJ, Hurd LB, Su CG, Keilbaugh SA, Lazar MA, Wu GD: An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitis. Am J Gastroenterol 2001, 96:3323–3328.PubMed
                21. Wada K, Nakajima A, Blumberg RS: PPARgamma and inflammatory bowel disease: a new therapeutic target for ulcerative colitis and Crohn's disease. Trends Mol Med 2001, 7:329–331.View ArticlePubMed
                22. Dello Russo C, Gavrilyuk V, Weinberg G, Almeida A, Bolanos JP, Palmer J, Pelligrino D, Galea E, Feinstein DL: Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes. J Biol Chem 2003, 278:5828–5836.View ArticlePubMed
                23. Feinstein DL, Spagnolo A, Akar C, Weinberg G, Murphy P, Gavrilyuk V, Dello RC: Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key? Biochem Pharmacol 2005, 70:177–188.View ArticlePubMed
                24. Maeshiba Y, Kiyota Y, Yamashita K, Yoshimura Y, Motohashi M, Tanayama S: Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys. Arzneimittelforschung 1997, 47:29–35.PubMed
                25. Haznedar MM, Buchsbaum MS, Hazlett EA, LiCalzi EM, Cartwright C, Hollander E: Volumetric analysis and three-dimensional glucose metabolic mapping of the striatum and thalamus in patients with autism spectrum disorders. Am J Psychiatry 2006, 163:1252–1263.View ArticlePubMed
                26. Kennedy DP, Redcay E, Courchesne E: Failing to deactivate: resting functional abnormalities in autism. Proc Natl Acad Sci U S A 2006, 103:8275–8280.View ArticlePubMed
                27. Gillies PS, Dunn CJ: Pioglitazone. Drugs 2000, 60:333–343.View ArticlePubMed
                28. Hanefeld M, Belcher G: Safety profile of pioglitazone. Int J Clin Pract Suppl 2001, 27–31.
                29. Saenger P, Dabiri G, Jones K, Krebs J, Sun Y, Mudd P, Weston WM, Cobitz AR, Freed MI, Porter LE: Diabetes in childhood - Benefits of rosiglitazone in children with type 2 diabetes mellitus. Program and abstracts of the European Association for the Study of Diabetes 41st Annual Meeting 2005, 133.
                30. Zdravkovic V, Hamilton JK, Daneman D, Cummings EA: Pioglitazone as adjunctive therapy in adolescents with type 1 diabetes. J Pediatr 2006, 149:845–849.View ArticlePubMed
                31. Landreth G: PPARgamma agonists as new therapeutic agents for the treatment of Alzheimer's disease. Exp Neurol 2006, 199:245–248.View ArticlePubMed
                32. Feinstein DL: Therapeutic potential of peroxisome proliferator-activated receptor agonists for neurological disease. Diabetes Technol Ther 2003, 5:67–73.View ArticlePubMed
                33. Gupta S, Aggarwal S, Heads C: Dysregulated immune system in children with autism: beneficial effects of intravenous immune globulin on autistic characteristics. J Autism Dev Disord 1996, 26:439–452.View ArticlePubMed
                34. Singh VK: Plasma increase of interleukin-12 and interferon-gamma. Pathological significance in autism. J Neuroimmunol 1996, 66:143–145.View ArticlePubMed
                35. Zingarelli B, Sheehan M, Hake PW, O'Connor M, Denenberg A, Cook JA: Peroxisome proliferator activator receptor-gamma ligands, 15-deoxy-Delta(12,14)-prostaglandin J2 and ciglitazone, reduce systemic inflammation in polymicrobial sepsis by modulation of signal transduction pathways. J Immunol 2003, 171:6827–6837.PubMed
                36. Diab A, Deng C, Smith JD, Hussain RZ, Phanavanh B, Lovett-Racke AE, Drew PD, Racke MK: Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. J Immunol 2002, 168:2508–2515.PubMed
                37. O'Byrne PM: Cytokines or their antagonists for the treatment of asthma. Chest 2006, 130:244–250.View ArticlePubMed
                38. Mueller C, Weaver V, Vanden Heuvel JP, August A, Cantorna MT: Peroxisome proliferator-activated receptor gamma ligands attenuate immunological symptoms of experimental allergic asthma. Arch Biochem Biophys 2003, 418:186–196.View ArticlePubMed
                39. Marteleto MR, Pedromonico MR: Validity of Autism Behavior Checklist (ABC): preliminary study. Rev Bras Psiquiatr 2005, 27:295–301.View ArticlePubMed
                40. Wadden NP, Bryson SE, Rodger RS: A closer look at the Autism Behavior Checklist: discriminant validity and factor structure. J Autism Dev Disord 1991, 21:529–541.View ArticlePubMed
                41. Volkmar FR, Cicchetti DV, Dykens E, Sparrow SS, Leckman JF, Cohen DJ: An evaluation of the Autism Behavior Checklist. J Autism Dev Disord 1988, 18:81–97.View ArticlePubMed
                42. Comi AM, Zimmerman AW, Frye VH, Law PA, Peeden JN: Familial clustering of autoimmune disorders and evaluation of medical risk factors in autism. J Child Neurol 1999, 14:388–394.View ArticlePubMed
                43. Sweeten TL, Bowyer SL, Posey DJ, Halberstadt GM, McDougle CJ: Increased prevalence of familial autoimmunity in probands with pervasive developmental disorders. Pediatrics 2003, 112:e420.View ArticlePubMed
                44. Molloy CA, Morrow AL, Meinzen-Derr J, Dawson G, Bernier R, Dunn M, Hyman SL, McMahon WM, Goudie-Nice J, Hepburn S, Minshew N, Rogers S, Sigman M, Spence MA, Tager-Flusberg H, Volkmar FR, Lord C: Familial autoimmune thyroid disease as a risk factor for regression in children with Autism Spectrum Disorder: a CPEA Study. J Autism Dev Disord 2006, 36:317–324.View ArticlePubMed
                45. Gupta S, Aggarwal S, Rashanravan B, Lee T: Th1- and Th2-like cytokines in CD4+ and CD8+ T cells in autism. J Neuroimmunol 1998, 85:106–109.View ArticlePubMed
                46. Singh VK, Warren RP, Odell JD, Cole P: Changes of soluble interleukin-2, interleukin-2 receptor, T8 antigen, and interleukin-1 in the serum of autistic children. Clin Immunol Immunopathol 1991, 61:448–455.View ArticlePubMed
                47. Warren RP, Yonk LJ, Burger RA, Cole P, Odell JD, Warren WL, White E, Singh VK: Deficiency of suppressor-inducer (CD4+CD45RA+) T cells in autism. Immunol Invest 1990, 19:245–251.View ArticlePubMed
                48. Yonk LJ, Warren RP, Burger RA, Cole P, Odell JD, Warren WL, White E, Singh VK: CD4+ helper T cell depression in autism. Immunol Lett 1990, 25:341–345.View ArticlePubMed
                49. Lee KS, Park SJ, Hwang PH, Yi HK, Song CH, Chai OH, Kim JS, Lee MK, Lee YC: PPAR-gamma modulates allergic inflammation through up-regulation of PTEN. FASEB J 2005, 19:1033–1035.View ArticlePubMed
                50. Saubermann LJ, Nakajima A, Wada K, Zhao S, Terauchi Y, Kadowaki T, Aburatani H, Matsuhashi N, Nagai R, Blumberg RS: Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis. Inflamm Bowel Dis 2002, 8:330–339.View ArticlePubMed
                51. Zheng W, Flavell RA: The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 1997, 89:587–596.View ArticlePubMed
                52. Zhu J, Min B, Hu-Li J, Watson CJ, Grinberg A, Wang Q, Killeen N, Urban JF Jr., Guo L, Paul WE: Conditional deletion of Gata3 shows its essential function in T(H)1-T(H)2 responses. Nat Immunol 2004, 5:1157–1165.View ArticlePubMed
                53. Owley T, Walton L, Salt J, Guter SJ Jr., Winnega M, Leventhal BL, Cook EH Jr.: An open-label trial of escitalopram in pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 2005, 44:343–348.View ArticlePubMed
                54. King BH, Wright DM, Handen BL, Sikich L, Zimmerman AW, McMahon W, Cantwell E, Davanzo PA, Dourish CT, Dykens EM, Hooper SR, Jaselskis CA, Leventhal BL, Levitt J, Lord C, Lubetsky MJ, Myers SM, Ozonoff S, Shah BG, Snape M, Shernoff EW, Williamson K, Cook EH Jr.: Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiatry 2001, 40:658–665.View ArticlePubMed
                55. Arnold LE, Aman MG, Cook AM, Witwer AN, Hall KL, Thompson S, Ramadan Y: Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry 2006, 45:1196–1205.View ArticlePubMed
                56. Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, Dunbar F: Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004, 114:e634-e641.View ArticlePubMed
                57. Resetkova E, Morita T, Akasu F, Carayon P, Volpe R: In vitro effects of cytokines and human thyroglobulin on the induction of antibody-secreting cells in patients with auto-immune thyroid disease. Clin Invest Med 1993, 16:256–264.PubMed
                58. Shah Y, Morimura K, Gonzalez F: Expression of Peroxisome Proliferator-Activated Receptor-{gamma} in Macrophage Suppresses Experimentally-Induced Colitis. Am J Physiol Gastrointest Liver Physiol 2006.
                59. Dubuquoy L, Rousseaux C, Thuru X, Peyrin-Biroulet L, Romano O, Chavatte P, Chamaillard M, Desreumaux P: PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut 2006, 55:1341–1349.View ArticlePubMed
                60. Snider LA, Swedo SE: PANDAS: current status and directions for research. Mol Psychiatry 2004, 9:900–907.View ArticlePubMed
                61. Swedo SE, Garvey M, Snider L, Hamilton C, Leonard HL: The PANDAS subgroup: recognition and treatment. CNS Spectr 2001, 6:419–6.PubMed


                © Boris et al. 2007

                This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.